EMA recommends prasterone for VVA in postmenopausal women


eMediNexus    12 November 2017

The European Medicines Agency Committee for Medicinal Products for Human Use CHMP has recommended marketing authorization for prasterone Intarosa for the treatment of postmenopausal women with vulvar and vaginal atrophy and moderate to severe symptoms.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.